Immunohistochemical and molecular detection of the expression of FGF23 in phosphaturic mesenchymal tumors including the non-phosphaturic variant
Open Access
- 9 March 2016
- journal article
- research article
- Published by Springer Nature in Diagnostic Pathology
- Vol. 11 (1) , 26
Abstract
Phosphaturic mesenchymal tumors (PMTs) are rare neoplasms that are often associated with tumor-induced osteomalacia (TIO) due to excessive serum levels of fibroblast growth factor 23 (FGF23). PMTs share overlapping histologic features with other types of tumors; thus, accurate pathological diagnosis may be challenging. We performed an immunohistochemical examination of FGF23 expression in PMTs and other types of tumors, together with pertinent molecular analyses. Seven PMTs (5 with TIO and 2 without TIO) and 46 other types of bone and soft tissue tumors were retrieved, and immunohistochemistry was performed using a commercially available anti-FGF23 antibody. In addition, FGF23 mRNA expression was detected by reverse transcription-polymerase chain reaction (RT-PCR), using RNA extracted from formalin-fixed, paraffin-embedded tissues. Immunohistochemical analysis of FGF23 expression showed distinct, punctate staining in the cytoplasm in 5 PMTs with TIO, whereas FGF23 expression was negative in the 2 PMTs without TIO and the other 46 tumors. FGF23 mRNA expression was detected in all 4 PMTs examined, as well as in 1 chondromyxoid fibroma and 1 myxoid liposarcoma. The real-time RT-PCR data showed that the relative expression levels of the FGF23 mRNA tended to be higher in PMTs with TIO than in PMTs without TIO, or in the chondromyxoid fibroma specimen. Our data suggested that the feasibility of immunohistochemical detection of FGF23 may depend on the level of secreted FGF23 from tumor cells. Thus, immunohistochemistry for FGF23 is an useful diagnostic adjunct for PMT, although its utility appears to be limited in cases without TIO.Keywords
This publication has 27 references indexed in Scilit:
- Frequent expression of fibroblast growth factor-23 (FGF23) mRNA in aneurysmal bone cysts and chondromyxoid fibromasJournal of Clinical Pathology, 2012
- Matrix extracellular phosphoglycoprotein is expressed in causative tumors of oncogenic osteomalaciaJournal of Bone and Mineral Metabolism, 2011
- Malignant phosphaturic mesenchymal tumor of the larynxThe Laryngoscope, 2011
- CO2 laser ablation and balloon dilation for acquired nasopharyngeal stenosis: A novel techniqueThe Laryngoscope, 2011
- RT-PCR Analysis for FGF23 Using Paraffin Sections in the Diagnosis of Phosphaturic Mesenchymal Tumors With and Without Known Tumor Induced OsteomalaciaAmerican Journal of Surgical Pathology, 2009
- Juxtacortical Chondromyxoid Fibroma of Bone: A Unique VariantAmerican Journal of Surgical Pathology, 2007
- 1α,25-Dihydroxyvitamin D3upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transportAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2005
- Immunophenotype of Desmoplastic Small Round Cell Tumors as Detected in Cases with EWS-WT1 Gene Fusion ProductLaboratory Investigation, 2003
- Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or ricketsCancer, 1987
- DISTINCTIVE TUMOURS OF BONE AND SOFT TISSUE CAUSING ACQUIRED VITAMIN-D-RESISTANT OSTEOMALACIAThe Lancet, 1972